The quality of Bosnalijek's products and 59 years of experience are Bosnalijek's competitive advantages in Algeria, said Dr. Kamel Guesmi, director of Bosnalijek's representative office in this African country.During his recent visit to Bosnalijek, Dr. Guesmi confirmed that Bosnalijek, regardless of strong competition, would secure its place on the Algerian market.
The World Health Organization (WHO) has recognized only The Algerian National Drug Laboratory on the entire African continent. This country has very specific regulatory constraints and competitors from all over the world -especially from Jordan, Saudi Arabia, China and India.
''Bosnalijek can offer a high quality product which meets the requirements of the Algerian Ministry of Health, and in contrast to competition, can offer case study results, such as the ones for the drug Lopril whose chances on this market are great''.
According to Dr. Guesmi, Lopril, i.e. Enzypril is going to be a great success on the Algerian market where 3 million of inhabitants are affected by hypertension. Bosnalijek's products, Enzypril and Rhinostop, are currently going through a registration procedure in Algeria, which should be completed within a six months period.
Apart from having a great market for drug placement, Algeria also offers possibilities for the transfer of technologies and know-how in the field of pharmaceutical production. Namely, according to the current regulations in force in this country, the manufacturer is obliged, two years upon registration of its products, to start the production of these very products in Algeria.